61 related articles for article (PubMed ID: 7920310)
1. Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection.
Avery RK; Arav-Boger R; Marr KA; Kraus E; Shoham S; Lees L; Trollinger B; Shah P; Ambinder R; Neofytos D; Ostrander D; Forman M; Valsamakis A
Transplantation; 2016 Oct; 100(10):e74-80. PubMed ID: 27495775
[TBL] [Abstract][Full Text] [Related]
2. Resource Use and Financial Impact of Oral Step-Down Therapy for Resistant Cytomegalovirus in Solid Organ Transplant Recipients.
Kleiboeker H; Descourouez JL; Schulz LT; Mandelbrot DA; Odorico JS; Saddler CM; Smith JA; Jorgenson MR
Transplant Proc; 2024 Mar; 56(2):434-439. PubMed ID: 38355369
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment with ganciclovir for cytomegalovirus duodenitis following allogenic bone marrow transplantation.
Ahn JH; Lee JH; Lee KH; Kim WK; Lee JS; Bahng H; Jung HY; Kim YS; Kim O; Kim SH
Korean J Intern Med; 1999 Jan; 14(1):91-4. PubMed ID: 10063321
[TBL] [Abstract][Full Text] [Related]
4. Retrospective Evaluation of Cystatin C as a Measure of Renal Function in Pediatric Hematopoietic Stem Cell Transplant Patients Receiving Foscarnet for Cytomegalovirus Reactivation.
Pickett LR; Daukshus NP; Camacho-Bydume C; Mathew S; Mauguen A; Cohen N; Cancio M
Pediatr Infect Dis J; 2024 May; 43(5):457-462. PubMed ID: 38190640
[TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus in Adult Allogeneic Blood and Marrow Transplant Patients Before or Around the Period of Neutrophil Recovery: A Single-Center, Retrospective, Descriptive Study.
Martin I; Valsamakis A; Gladstone D; Jones R; Ambinder R; Avery RK
Open Forum Infect Dis; 2020 Mar; 7(3):ofaa081. PubMed ID: 32258204
[TBL] [Abstract][Full Text] [Related]
6. Safety of alternative antiviral agents for neonatal herpes simplex virus encephalitis and disseminated infection.
Wang Y; Smith KP
J Pediatr Pharmacol Ther; 2014 Apr; 19(2):72-82. PubMed ID: 25024666
[TBL] [Abstract][Full Text] [Related]
7. At-Home Foscarnet Administration in Patients with Cytomegalovirus Infection Post-Allogeneic Stem Cell Transplantation: A Unicentric, Safe, and Feasible Program.
Ruiz-Boy S; Pedraza A; Prat M; Salas MQ; Carcelero E; Riu-Viladoms G; Suárez-Lledó M; Monge-Escartín I; Rodríguez-Lobato LG; Martínez-Roca A; Rovira M; Martínez C; Gallego C; Urbano-Ispizua Á; Sánchez J; Marcos MÁ; Fernández-Avilés F
Pharmaceuticals (Basel); 2023 Dec; 16(12):. PubMed ID: 38139867
[TBL] [Abstract][Full Text] [Related]
8. Foscarnet treatment of cytomegalovirus infection in haploidentical or unrelated donor transplants.
Metafuni E; Chiusolo P; Sica S; Laurenti L; Bregante S; Van Lint MT; Dominietto A; Angelucci E; Bacigalupo A
Bone Marrow Transplant; 2018 Dec; 53(12):1560-1567. PubMed ID: 29795416
[TBL] [Abstract][Full Text] [Related]
9. Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants.
Meijer E; Boland GJ; Verdonck LF
Clin Microbiol Rev; 2003 Oct; 16(4):647-57. PubMed ID: 14557291
[TBL] [Abstract][Full Text] [Related]
10. Alkylglycerol prodrugs of phosphonoformate are potent in vitro inhibitors of nucleoside-resistant human immunodeficiency virus type 1 and select for resistance mutations that suppress zidovudine resistance.
Hammond JL; Koontz DL; Bazmi HZ; Beadle JR; Hostetler SE; Kini GD; Aldern KA; Richman DD; Hostetler KY; Mellors JW
Antimicrob Agents Chemother; 2001 Jun; 45(6):1621-8. PubMed ID: 11353603
[TBL] [Abstract][Full Text] [Related]
11. Quantitation of cytomegalovirus: methodologic aspects and clinical applications.
Boeckh M; Boivin G
Clin Microbiol Rev; 1998 Jul; 11(3):533-54. PubMed ID: 9665982
[TBL] [Abstract][Full Text] [Related]
12. Management of cytomegalovirus infection after solid-organ or stem-cell transplantation. Current guidelines and future prospects.
Hebart H; Kanz L; Jahn G; Einsele H
Drugs; 1998 Jan; 55(1):59-72. PubMed ID: 9463790
[TBL] [Abstract][Full Text] [Related]
13. Forscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study.
Moretti S; Zikos P; Van Lint MT; Tedone E; Occhini D; Gualandi F; Lamparelli T; Mordini N; Berisso G; Bregante S; Bruno B; Bacigalupo A
Bone Marrow Transplant; 1998 Jul; 22(2):175-80. PubMed ID: 9707026
[TBL] [Abstract][Full Text] [Related]
14. Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allogeneic bone marrow transplantation (BMT): a dose-finding study.
Bregante S; Bertilson S; Tedone E; Van Lint MT; Trespi G; Mordini N; Berisso G; Gualandi F; Lamparelli T; Figari O; Benvenuto F; Raiola AM; Bacigalupo A
Bone Marrow Transplant; 2000 Jul; 26(1):23-9. PubMed ID: 10918402
[TBL] [Abstract][Full Text] [Related]
15. Combined foscarnet -ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation (Hsct).
Bacigalupo A; Bregante S; Tedone E; Isaza A; Van Lint MT; Moro F; Trespi G; Occhini D; Gualandi F; Lamparelli T; Marmont AM
Bone Marrow Transplant; 1996 Nov; 18 Suppl 2():110-4. PubMed ID: 8932810
[TBL] [Abstract][Full Text] [Related]
16. Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation.
Stocchi R; Ward KN; Fanin R; Baccarani M; Apperley JF
Haematologica; 1999 Jan; 84(1):71-9. PubMed ID: 10091394
[TBL] [Abstract][Full Text] [Related]
17. Foscarnet in the management of cytomegalovirus infections in hematopoietic stem cell transplant patients.
Bacigalupo A; Boyd A; Slipper J; Curtis J; Clissold S
Expert Rev Anti Infect Ther; 2012 Nov; 10(11):1249-64. PubMed ID: 23167560
[TBL] [Abstract][Full Text] [Related]
18. Early treatment of CMV infections in allogeneic bone marrow transplant recipients with foscarnet or ganciclovir.
Bacigalupo A; van Lint MT; Tedone E; Moro F; Sanna MA; Longren M; Trespi G; Frassoni F; Occhini D; Gualandi F
Bone Marrow Transplant; 1994 Jun; 13(6):753-8. PubMed ID: 7920310
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
